Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M384Revenue $M110Net Margin (%)-36.3Altman Z-Score1.3
Enterprise Value $M240EPS $-0.9Operating Margin %-36.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-36.3Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %--Quick Ratio3.2Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %--Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow37.4y-y EBITDA Growth Rate %-223.7ROA % (ttm)-19.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-26.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M43.1ROIC % (ttm)-459.6Gross Margin Increase y-yN

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2015-06-30 Reduce$9.09 - $13.42
($10.76)
$ 8.90-17%Reduce -0.09%3,946,500
VNDAJohn Paulson 2015-03-31 Add0.02%$8.99 - $14.58
($11.3)
$ 8.90-21%Add 8.97%3,950,000
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 8.90-33%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 8.90-37%New holding1,392,500
VNDAFirst Eagle Investment 2013-09-30 Sold Out -0.024%$8.05 - $13.03
($10.66)
$ 8.90-17%Sold Out0
VNDAFirst Eagle Investment 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 8.9032%Reduce -48.99%975,000
VNDAFirst Eagle Investment 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 8.90151%Add 43.16%1,911,452
VNDAFirst Eagle Investment 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 8.90-19%Add 111.12%752,375
VNDAFirst Eagle Investment 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 8.90-18%New holding356,375
VNDAFirst Eagle Investment 2009-06-30 Sold Out $0.9 - $14.64
($7.49)
$ 8.9019%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.96-0.67view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.96-0.67view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.96-0.67view
Flynn James E 2015-12-16Buy11,170$8.97-0.78view
Flynn James E 2015-12-11Buy1,201,364$8.386.21view
Flynn James E 2015-12-11Buy425,982$8.63.49view
Polymeropoulos Mihael HristosPresident and CEO 2015-09-10Sell131,739$12.68-29.81view
Polymeropoulos Mihael HristosPresident and CEO 2015-05-22Sell186,395$10.36-14.09view
Polymeropoulos Mihael HristosPresident and CEO 2015-03-10Sell21,900$10.53-15.48view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2015-03-10Sell12,450$10.53-15.48view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 14 2016
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016 Apr 14 2016
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies Apr 12 2016
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 4, 2016 Apr 04 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Apr 04 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April... Apr 01 2016
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions Mar 28 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 25 2016
Dermatologists Praise Multiple Benefits of Oculus Innovative Science's Microcyn Technology Mar 08 2016
Edited Transcript of VNDA earnings conference call or presentation 27-Oct-14 2:00pm GMT Feb 29 2016
Can You Make Money With These Biotech Stocks? VNDA, ICPT, PTLA, and ACOR Feb 25 2016
VANDA PHARMACEUTICALS INC. Financials Feb 17 2016
D.C. pharma's drug for jet lag moves closer to takeoff Feb 16 2016
Vanda Pharmaceuticals, Inc. Earnings Analysis: Q4, 2015 By the Numbers Feb 12 2016
VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Feb 12 2016
Edited Transcript of VNDA earnings conference call or presentation 10-Feb-16 9:30pm GMT Feb 11 2016
Vanda reports 4Q loss Feb 10 2016
Vanda reports 4Q loss Feb 10 2016
Vanda reports 4Q loss Feb 10 2016
Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Feb 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)